Association Of Circulating Omega-3 Fatty Acids and Cardiometabolic Outcomes: A Systematic Review of Publications from UK Biobank

heart disease, cardiovascular disease or stroke; incidence of type-2 diabetes, non-alcoholic fatty liver disease, or metabolic dysfunction-associated steatotic liver disease; mortality from liver disease. METHODSSearch strategy Literature searching in MEDLINE, EMBASE and CINAHL.Searches using keywords and their alternative terms, such as ("omega 3", "omega-3", "polyunsaturated fatty acid", "eicosapentaenoic acid", "docosahexaenoic acid ", "EPA", "DHA") and ("UK Biobank", "UK BioBank"). P a r t i c i p a n t o r p o p u l a t i o n U K B i o b a n k participants.Intervention Omega-3 fatty acids (total, EPA, DHA, non-DHA) in blood plasma.Comparator High omega-3 vs low omega-3 levels (e.g.across tertiles, quartiles or quintiles) or omega-3 levels as a continuum.Study designs to be included Cross-sectional or longitudinal follow-up. Eligibility criteriaReported a clinically relevant outcome; Reported omega-3 fatty acid concentrations in plasma; Publication available as a full-text article;